| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.8 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | 0.0098 | 0.8 |
| mRNA | IU1 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0086 | 0.8 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | 0.0098 | 0.8 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.0095 | 0.8 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.8 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | -0.0093 | 0.8 |